Never miss a story

Get subscribed to our newsletter

Photo by Unsplash

AZD2816 will be given as two doses, four or twelve weeks apart.

British-Swedish biopharmaceutical firm AstraZeneca has in partnership with the University of Oxford rolled out human trials for booster shots against the Beta Covid variant.

The booster shot, named AZD2816, will be administered to individuals who have previously been fully vaccinated with two doses of AstraZeneca vaccine/Vaxzervia or an mRNA vaccine, at least three months after their last injection.

Follow NewsGram on Facebook to stay updated.

In non-vaccinated individuals, AZD2816 will be given as two doses, four or twelve weeks apart, or given as a second dose following a first dose of AstraZeneca vaccine/Vaxzervia --four weeks apart, the company said in a statement on Sunday.

AZD2816 has been designed using the same adenoviral vector platform as AstraZeneca vaccine/ Vaxzervia, with minor genetic alterations to the spike protein based on the Beta (B1351) variant, first identified in South Africa.

The study aims to enrol 2,250 participants from the UK, South Africa, Brazil and Poland to build immunity against the Beta Covid variant.

"Testing booster doses of existing vaccines and new variant vaccines are important to ensure we are best prepared to stay ahead of the pandemic coronavirus, should their use be needed," said Professor Sir Andrew J. Pollard, chief investigator and director of the Oxford Vaccine Group, in the statement.

Initial data from the trial is expected later this year and, once available, will be submitted to regulators for assessment as a next-generation booster vaccine and through an expedited regulatory pathway, the company said.

"The Beta variant vaccine contains 10 changes across the spike protein, many of which are also seen in other variants of concern, and which lead to effects such as, reduced ability of antibodies induced against the original virus to block cell entry (K417N, E484K, N501Y), increased infectivity compared to the original virus (D614G); reduced sensitivity of neutralising antibodies to the original virus (L452R)," the company said.

Besides these minor modifications, the two AZD2816 and AstraZeneca vaccine/ Vaxzervia vaccines are the same, it noted.

In May, the UK launched a clinical trial that aimed to assess the efficacy of a third 'booster' dose of seven different Covid-19 vaccines -- Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, Novavax, Valneva, Janssen and Curevac -- on patients immune responses.

It costs 19.3 million pounds and is being funded by the UK government and led by the University Hospital Southampton NHS Foundation Trust.

Covid While Johnson & Johnson is studying the need for a second dose to raise protection against the virus. Photo by Unsplash

Meanwhile, the US Centers for Disease Control and Prevention has noted that there is currently no data to support that a Covid-19 vaccine booster shot is needed for the general population. But, an extra dose may be needed for more vulnerable groups, such as older adults or organ transplant patients.

ALSO READ Motherhood covid-19

Both Pfizer and Moderna are investigating a third dose of the Covid vaccine, while Johnson & Johnson is studying the need for a second dose to raise protection against the virus, the report said.

The US NIH's National Institute of Allergy and Infectious Disease, or NIAID, is also conducting a clinical trial to understand whether the third shot of a Moderna vaccine could be given after a person initially received two shots of Pfizer or one shot of Johnson & Johnson, the report added. (IANS/AD)


wikimedia commons

Mortgage loan graph

By- Blogger Indifi

EMI is known as equated monthly installments. It is a fixed payment made by the borrower each month to repay the loan amount. The EMI is divided into two loan components. One is the principal amount, and the second is the interest amount. Whether you are applying for a personal loan, business loan, home loan, car loan, or education loan, EMIs are easy to calculate using the EMI loan calculator.

Keep Reading Show less
Photo by Flickr.

Swastika, one of the sacred symbols used by many religions like Hinduism, Jainism, and Buddhism.

The symbol of Swastika is known to signify peace, prosperity, and good fortune in the religious cultures of Eurasia. In fact, this symbol is considered very significant in Hinduism, Buddhism, and Jainism. But, at the same time, it has become one of the most misunderstood religious symbols and has been globally banned in many countries.

The reason why the symbol of Swastika is banned in many countries is because of its association with Adolf Hitler's extreme political ideology, Nazism, as Swastika as its official symbol.

Keep Reading Show less

Since emerging into the public eye with a historic gold medal at the junior world championships in 2016, he has maintained a high level of performance

India celebrated a historic day on August 7, as 23-year-old Neeraj Chopra became the first Indian to win an Olympic gold medal in athletics. In the men's javelin throw event, he achieved his greatest triumph, throwing the javelin 87.58 meters on his second try.

Neeraj Chopra was born on December 24, 1997, in Khandra village in Haryana's Panipat district. He grew up in a Haryanavi family of farmers. He is the brother of two sisters. He graduated from Dayanand Anglo-Vedic College in Chandigarh and is now enrolled in Lovely Professional University in Jalandhar, Punjab, pursuing a Bachelor of Arts degree. Chopra was bullied due to his obesity as a kid, which prompted his father to enroll him in a nearby gym. He then joined a gym in Panipat, where Jaiveer Choudhary, a javelin thrower, noticed his potential and coached him. When the 13-year-old Chopra finished training under Jaiveer for a year, he was enrolled at the Tau Devi Lal Sports Complex in Panchkula, where he began training under coach Naseem Ahmed.

Keep reading... Show less